© 2003 BMJ Publishing Group & Royal College of Paediatrics and Child Health
LEADING ARTICLE
Endocrinology
Growth hormone therapy in the Prader-Willi syndrome
Department of Child Health, Royal Hospital for Sick Children, Yorkhill, Glasgow, UK
Correspondence to:
Correspondence to:
Dr M D C Donaldson, Department of Child Health, Royal Hospital for Sick Children, Yorkhill, Glasgow G3 8SJ, UK;
mdcd1t@clinmed.gla.ac.uk
Who should receive it and when?
Keywords: Prader-Willi syndrome; growth hormone
| The first 150 words of the full text of this article appear below. |
In November 2000 the Department of Health in England granted a licence to Pharmacia Limited for the use of their recombinant growth hormone, Genotropin (somatropin rbe), in the Prader-Willi syndrome. The indications for use were given as "improvement of body composition and growth". In this leading article we shall attempt to examine the role of growth hormone in the Prader-Willi syndrome by considering linear growth and body composition in untreated and treated individuals, the pathophysiology of the abnormal linear growth, and the scope for future research.
While the growth and body composition aspects of the Prader-Willi syndrome are important, they must be seen in the context of a disabling disorder with major implications for the individual and family.1 Therefore a brief account of the condition is in order.
The Prader-Willi syndrome results from loss of an imprinted gene or genes on the long arm of chromosome 15 within the
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
-
Delemarre, E. M, Felius, B., Delemarre-van de Waal, H. A
(2008). Inducing puberty. Eur J Endocrinol
159: S9-S15
[Abstract] [Full Text] -
Stafler, P, Wallis, C
(2008). Prader-Willi syndrome: who can have growth hormone?. Arch. Dis. Child.
93: 341-345
[Abstract] [Full Text] -
Paik, K., Jin, D., Song, S., Lee, J., Ko, S., Song, S., Kim, J., Oh, Y., Kim, S., Lee, S., Kim, S., Kwon, E., Choe, Y.
(2004). Correlation between Fasting Plasma Ghrelin Levels and Age, Body Mass Index (BMI), BMI Percentiles, and 24-Hour Plasma Ghrelin Profiles in Prader-Willi Syndrome. J. Clin. Endocrinol. Metab.
89: 3885-3889
[Abstract] [Full Text]
- Full Text
- Full Text (PDF)
- Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
- Citation Map
Services
- Email this link to a friend
- Similar articles in ADC Online
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
-
Drugs: CNS (not psychiatric)
-
Child health
-
Obesity (nutrition)
-
Health education
-
Obesity (public health)
Bookmark with
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
